ALLO
NASDAQ · Biotechnology
Allogene Therapeutics Inc
$2.07
-0.15 (-6.76%)
Open$2.23
Previous Close$2.22
Day High$2.26
Day Low$2.06
52W High$2.80
52W Low$0.86
Volume—
Avg Volume4.51M
Market Cap541.19M
P/E Ratio—
EPS$-0.87
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+963.3% upside
Current
$2.07
$2.07
Target
$22.01
$22.01
$17.29
$22.01 avg
$30.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.71M | 52.93M | 41.75M |
| Net Income | 7.77M | 8.17M | 5.40M |
| Profit Margin | 14.7% | 15.4% | 12.9% |
| EBITDA | 12.72M | 14.19M | 11.69M |
| Free Cash Flow | 7.78M | 12.29M | 5.60M |
| Rev Growth | +19.4% | -7.3% | -1.4% |
| Debt/Equity | 1.42 | 1.47 | 1.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |